Current and Emerging CAR T-Cell and Other Cellular Therapies for the Treatment of Patients with Hematologic Malignancies

This webcast is not certified for credit

Release Date: September 14, 2021
Expiration Date: September 13, 2022

Activity Overview
This webcast on The Treatment of Patients with Hematologic Malignancies was presented at #PPLC21 and features expert interpretation of emerging data and guidance regarding current and emerging therapies for the treatment of patients with lymphoma and multiple myeloma.

Target Audience
The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with
hematologic malignancies.

Learning Objectives
After participating in this activity, participants should be better able to:

  • Discuss the rationale for using cellular-based therapies for patients with hematologic malignancies
  • Evaluate the latest clinical trial data of current and emerging cellular therapies in patients with lymphoma and myeloma
  • Assess practical approaches to the use of cellular therapy, including patient referral and adverse event management strategies

Method of Participation
There are no fees for participating in this activity

Topics Presented
-Rationale for Cell Therapy in Patients with Lymphoma and Myeloma: Targeting CD19, BCMA, and Other Cellular Markers
-Review of the Latest Clinical Trial Data: Cell Therapy for Patients with Lymphoma
-Review of the Latest Clinical Trial Data: Cell Therapy for Patients with Multiple Myeloma
-Modifications to Enhance CAR-T cell Therapies
-Strategies for Bridging the Gap Between Academic and Community Practices: Referring Patients for Potentially Curative Therapy
-Expert Panel and Audience Q&A: Optimizing Safety of Cell Therapy in Patients with Hematologic Malignancies

Julie Vose, MD, MBA
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center 
Omaha, Nebraska

Nina Shah, MD
Associate Professor, Department of Medicine
Helen Diller Family Comprehensive Cancer Center
University of California San Francisco
San Francisco, California

Tara Graff, DO
Specializes in Hematology/Oncology
Mission Blood + Cancer 
Des Moines, Iowa

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:   

Julie Vose, MD, MBA
Morphosys (Self): Consultant (Status: Ongoing); AbbVie (Self): Consultant (Status: Ongoing); Pharmacyclics (Self): Consultant (Status: Ongoing); Astra-Zeneca (Self): Consultant (Status: Ongoing)

Nina Shah, MD
Glaxo Smith-Kline (Self): Consultant (Status: Ongoing); Amgen (Self): Consultant (Status: Ongoing); Indapta Therapeutics (Self): Consultant (Status: Ongoing);Sanofi (Self): Consultant (Status: Ongoing); CareDX (Self): Consultant (Status: Ongoing); Kite (Self): Consultant (Status: Ongoing);  Karyopharm (Self): Consultant (Status: Ongoing); Oncopeptides (Self): Consultant (Status: Ongoing); Celgene/Bristol Myers Squibb (Self): Research (Status: Ongoing); Janssen (Self): Research (Status: Ongoing); Bluebird Bio (Self): Research (Status: Ongoing); Sutro Biopharma (Self): Research (Status: Ongoing); Teneobio (Self): Research (Status: Ongoing); Poseida (Self): Research (Status: Ongoing); Nektar (Self): Research (Status: Ongoing)

Tara Graff, DO
Astra-Zeneca (Self): Consultant (Status: Ongoing); AbbVie (Self): Consultant (Status: Ongoing); TG Therapeutics (Self): Consultant (Status: Ongoing); Karyopharm (Self): Consultant (Status: Ongoing); BMS/Celgene (Self): Consultant (Status: Ongoing); Adaptive Biotech (Self): Consultant (Status: Ongoing)

Planning Committee
The following planning committee members have nothing to disclose:​
UNMC: Brenda Ram, CMP, CHCP​
Bio Ascend: Jennifer Bechan, CMP, HMCC; Lucja Grajkowska, PhD; Kraig Steubing

This activity is supported by educational grants from Bristol Myers Squibb and Legend Biotech.

Technical Requirements
This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.